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Summary 
Binding of L-selectin expressed on lymphocytes to carbohydrate ligand(s)  on lymph node high 
endothelial venules is thought to initiate lymphocyte extravasation from blood to lymph during 
recirculation and localization to sites of antigen (Ag) exposure. Previous studies have shown that 
treatment of lymphocytes with antibody to L-selectin (MEL-14) ablates trafficking to peripheral 
lymph nodes (PLN). In mice, naive but not memory CD4 cells express L-selectin.  To examine 
the role of L-selectin in helper T cell migration, we studied the effects of in vivo administration 
of MEL-14 on CD4 cell responses. Systemic exposure of mice to MEL-14 depleted CD4 cells 
expressing a naive phenotype (CD45RB hi, CD44  l~  from PLN but not from spleen. The ma- 
jority of residual lymph node CD4 cells exhibited the reciprocal, memory phenotype (CD45RB  l~ 
CD44hi). MEL-14 treatment prevented priming of naive CD4 cells for proliferation and cytokine 
production (IL-2 and IL-4) to keyhole limpet hemocyanin in PLN draining the site of Ag injection, 
but not in the spleen. The results suggest that naive cells were not depleted, but rather diverted 
to other sites where priming occurred. The data demonstrate that L-selectin mediates extravasation 
of naive CD4 cells into PLN and that its function cannot be replaced by other homing receptors. 
O 
ne of the characteristic features of the immune system 
is the continuous recirculation of small lymphocytes 
from blood to lymph that is thought to be essential both 
to immunologic surveillance for infectious pathogens and the 
rapid localization of Ag-specific lymphocytes to sites of Ag 
exposure.  Lymphocyte extravasation  between apposed en- 
dothelial cells into peripheral lymphoid tissues is initiated by 
adhesive interactions of tissue-specific homing receptors with 
ligands on the luminal surface of vascular endothelium (1). 
Adhesion to high endothelial venules of peripheral lymph 
nodes (PLN) in vitro is primarily mediated by the lymph 
node homing receptor, L-selectin, a carbohydrate-binding pro- 
tein (2) detected in the mouse by the MEL-14 antibody (3). 
L-selectin is initially acquired by mature thymocytes before 
exit to the periphery and entrance into the recirculating lym- 
phocyte pool (4, 5). It was initially postulated that expres- 
sion of L-selectin was required for lymphocyte recirculation 
to PLN on the basis of studies showing that lymphocytes 
treated with MEL-14  antibody (3) and L-selectin  negative 
cell lines (6) are unable to migrate into lymph nodes in vivo. 
L-selectin is shed after lymphocyte activation (7-10) but can 
be reexpressed upon return to a resting state (8) suggesting 
that loss of L-selectin permits localization of responding cells 
in sites of Ag exposure and that its reexpression  coincides 
with development of a memory state (11). However, we have 
shown that murine memory CD4 cells lack L-selectin  (12, 
13). In addition, CD4 cells expressing a naive phenotype (high 
levels of CD45R, low levels of adhesion molecules) appear 
to be the major population to recirculate  to PLN via high 
endothelial venules, while CD4 cells of the reciprocal, memory 
phenotype  principally enter lymph nodes via the afferent lymph 
(14). Because of the importance of understanding lympho- 
cyte trafficking  to develop strategies  for immune interven- 
tion in a variety of disease processes, we examined the in situ 
role of L-selectin in the migration of murine naive CD4 cells 
during primary immune responses. The data demonstrate that 
L-selectin is required for entry of naive CD4 cells into PLN 
and thus for development of primary CD4 responses in those 
sites. 
Materials  and Methods 
Mice.  C57BL/6 mice were purchased  from The Jackson Labo- 
ratory (Bar Harbor, ME). 
Antibodies.  Antibodies  were isolated by protein G purification 
(Pharmacia Fine Chemicals, Piscataway, NJ). Rat IgG2a was ob- 
tained from normal sera. MEb14 was purified from ascites. Anti- 
c~4 integrin (PS/2.3) was a gift of Sherman  Fong (Genentech, Inc., 
S. San Francisco, CA). Antibodies for depletion of T and B cells 
have been described (15) and include anti-Thy 1.2 (FTD5 and 
HO.13.14), anti-CD4  (RL.172.4), anti-CD8  (HO.2.2,  AD4), 
anti-class II (D3.137), and anti-HSA  011d). Antibodies  for staining 
included:  CD44  (Pgp-1) IM7.8.1),  L-selectin (MEL-14), and 
CD45RB (23G2). Rat IgG2a, and IgG2b isotype controls were 
from PharMingen (Sorrento Valley, CA).  Anti-rat  r  antibody 
(RG7/9.1) was conjugated to FITC. PE-anti-CD4 (GK1.5) was 
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lowing anti-cytokine or anti-cytokine receptor antibodies were used: 
7D4 and PC.61 (anti-IL-2R); 11Bll (anti-IL-4); and XMG1.2 and 
R46A2 (anti-IFN-"/). Hamster anti-mouse CD3 (2Cll) was from 
culture supernatants.  Peroxidase-labeled goat anti-rat IgG was from 
Caltag Laboratories (San Francisco,  CA). 
CD4 Cell Preparation.  Primary effector cells were induced by 
s.c. injection of mice with 200/zg KLH (Calbiochem Corp., La 
Jolla, CA) in CFA at the base of the tail, 5 d before use (16). CD4 
cells were er~riched to >80% from periaortic lymph nodes and/or 
pooled inguinal and brachial lymph nodes, or spleens by depletion 
of CD8 cells and B cells with anti-CD8, anti-class II, and anti- 
HSA  antibodies,  and rabbit  and  guinea  pig C  (GIBCO BRL, 
Gaithersburg, MD). 
APC Preparation.  Normal spleen cells, depleted of T cells with 
a mixture of antioThy.l.2,  anti-CD8, and anti-CD4 antibodies and 
C were used as APC. For anti-CD3 responses,  APC were treated 
for 30 min at 37°C with 25/~g/ml mitomycin C (Sigma Chemical 
Co., St. Louis, MO). For KLH-specific responses, APC were cul- 
tured for 18 h in 100-mm petri dishes (Fisher Scientific, Pittsburgh, 
PA) at 5  x  106 ml in RPMI  1640 (Irvine Scientific, Santa Ana, 
CA) supplemented with 7% FCS (Hyclone Laboratories,  Logan, 
UT), 100 #g/ml penicillin,  100 U/ml streptomycin, 4 mM r-glu- 
tamine,  10 mM Hepes,  and 5  x  10 -s M  2-ME and with  100 
/~g/ml  KLH before treatment with mitomycin C. 
Flow Cytometry.  Expression ofCD44, L-selectin, and CD45RB 
was analyzed as described (12). CD4 ÷ cells were stained with the 
indicated monoclonal antibodies, followed by FITC-anti-rat K an- 
tibody, and PE-anti-CD4. 
In Vitro Restimulation of CD4 Cells.  For KLH responses, CD4 
cells were cultured at the indicated concentrations in triplicate in 
200/~1 supplemented RPMI with 2  x  10  s Ag-pulsed APC in 96- 
well flat-bottomed plates (Costar Corp., Cambridge, MA). For anti- 
CD3 stimulation, wells were pretreated with 10/~g/ml 2Cll for 
2 h at 37°C and CD4 cells were cultured with 10  s APC. Super- 
natants were harvested after 48 h. To assess proliferation, CD4 cells 
cultured  under  the  above  conditions  were pulsed  with  1  #Ci 
[3H]thymidine at 48 h and harvested 18 h later. 
Cytokine Assays.  The cytokine assays have been previously de- 
scribed (13). Cytokines in culture supernatants were referenced to 
rlL-2, rlL-4, and rlFN-3, from X63.AgS-653 cells transfected with 
murine cDNA for the respective cytokines (17). IL-2 and IL-4 were 
detected by proliferation of the NK cell line (18) which responds 
to both cytokines, but is specific  for IL-2 when IL-4  activity is blocked 
by 11Bll antibody, and specific for IL-4 when IL-2 activity is blocked 
by  the  anti-IL-2R  antibodies,  7D4  and  PC.61.  Data  are  half- 
maximum units where I U of IL-2 equals 14 pg protein, and I U 
of IL-4 equals 0.7 pg protein. IFN-y was detected by ELISA using 
R46A2 as coating antibody and biotinylated-XMG1.2  as the second 
step reagent. Data are units per milliliter where 1 U of IFN-3~ equals 
0.1  ng protein. 
Serum MEL-14.  The presence of MEL-14 in sera was measured 
by ELISA  as described  (19) using L-selectin-Ig for capture and 
purified MEL-14 antibody as the standard. 
Results 
To assess  the role of L-selectin in lymphocyte migration 
to PLN, groups of four to six C57BL/6 mice were injected 
i.v.  with  a  single dose of 250/~g  MEL-14 antibody,  or of 
rat IgG2a as an isotype control.  18 h  later,  mice were im- 
munized by s.c. injection of 200 #g KLH in CFA. The half- 
life of MEL-14 in the serum was 5-6 d, at which time cir- 
culating  levels of MEL-14 ranged  from 33  _+  5  to  51  _+ 
7/~g/ml. At day 6, a 10-50-fold reduction in PLN cellularity 
(pooled inguinal, brachial, and periaortic lymph nodes) was 
observed in mice treated with MEL-14 as compared with iso- 
type control-treated animals (Fig. 1). In contrast, there was 
a 22% increase in the spleen cell number after MEL-14 treat- 
ment. These results suggest that most of the cells in the PLN 
are in the continuously recirculating pool and depend upon 
L-selectin for entry into PLN, but not spleen. Similar changes 
were  seen  in  five  additional  experiments,  irrespective  of 
whether  KLH was  injected. 
In parallel experiments (not shown), PLN draining the site 
of KLH injection (periaortic lymph nodes) from control mice 
exhibited histologic changes typically associated with a pri- 
mary immune response including  marked lymph node en- 
largement due to lymphoid proliferation and prominent ger- 
minal centers in the lymphoid follicles. In contrast, PLN from 
MEL-14-treated  animals  were  atrophied,  lacked  germinal 
centers and zones of lymphoid expansion, and contained only 
mature resting lymphocytes. Thus, treatment with MEL-14 
prevented induction of histological changes associated with 
a primary immune response in lymph nodes. Despite the large 
decrease in  the lymph node cellularity in MEL-14-treated 
animals,  the proportions of CD4 + and CD8 + T  cells, and 
B220 bearing B lymphocytes were similar to those of PLN 
from mice treated with irrelevant IgG2a (not shown), indi- 
cating that MEL-14 antibody did not selectively affect recir- 
culation of these populations and that approximately equal 
proportions  of each  cell  type  were  excluded  by  MEL-14 
treatment. 
MEL-I4 Blocks Priming of CD4 Cells in Lymph Nodes.  To 
evaluate effects of MEL-14 treatment on CD4 cell function, 
primary effector cells were generated by immunization with 
KLH as above, 1 d  after i.v.  injection of MEL-14 or IgG2a 
antibody. CD4 cells were isolated from periaortic lymph nodes 
draining the site of Ag injection and from spleen, 5 d  after 
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Figure  1.  Effects  of in vivo treatment with MEL-14 antibody on pe- 
ripheral lymph nodes. A single dose of 250 #g MEL-14, or of rat IgG2a 
was administered  i.v. to groups of four to six mice 18 h before s.c. injection 
of 200/zg KLH/CFA. 5 d later, the total numbers of nucleated cells from 
PLN (pooled inguinal, brachial, and periaortic lymph nodes) and spleen 
were determined. 
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KLH-spedfic proliferation (Fig.  2 A),  and IL-2 and IL-4 
production (Fig.  2,  B  and  C) by CD4  ceils from MEL- 
14-treated animals  were negligible compared with the re- 
sponses obtained from control CD4 cells. In contrast, Ag- 
specific  responses of splenic CD4 cells were unaffected by MEL- 
14 treatment (Fig. 2, A-C).  Similar results  were obtained 
in three additional experiments. 
As a specificity control, we compared the in vivo effects 
of MEL-14 to an identical dose of an antibody to cx4 integrin 
(PS/2) (20), an IgG2b antibody which binds to 90% of CD4 
cells and blocks homing to Peyer's patches but not lymph 
nodes in vivo (21). In two experiments, anti-oe4 had no effect 
on cell recovery from PLN or spleen and, by comparison with 
an isotype-matched control, did not diminish development 
of KLH-spedfic primary effector  CD4  cells  (assessed by 
proliferation and cytokine production) in either site  (not 
shown). In other studies, an anti-CD44 antibody of the IgG2a 
isotype, IRAWB14.4 (22),  which binds to nearly all lym- 
phocytes from PLN and spleen blocked contact sensitivity 
responses but not homing to PLN (23).  We conclude that 
the in vivo effects of MEL-14 treatment are due to the ca- 
pacity  to  bind  L-selectin  rather  than  some  nonspecific 
mechanism. 
To evaluate the functional potential of the CD4 popula- 
tion that remained in the lymph nodes after MEL-14 treat- 
ment, we examined the response to plate bound anti-CD3. 
Proliferation (Fig. 3 A), as weU as IL-2,  IL-4,  and IFN-3' 
secretion (Fig. 3 B) comparable to that of control CD4 cells 
was elicited from residual lymph node CD4 cells. Thus, the 
few remaining lymph node CD4 cells were not adversely 
affected by the MEL-14 antibody. Comparable results were 
obtained in two additional experiments. 
Surface Phenot~e of  CD4 Cells  After In Vivo  MEL-14 Treat- 
merit,  We analyzed the surface phenotype of lymph node 
and splenic CD4 calls 6 d after exposure to MEL-14  (Fig. 
4 A).  As  expected,  lymph node CD4 cells from control 
animals had a predominantly naive phenotype: L-selectin hi, 
CD45RB  hi, and CD44  l~ (1, 24, 25). In contrast, CD4 cells 
from MEL-14-treated mice lacked L-sdectin, a majority were 
CD45RB l~ and at least half were  CD44  hi, a phenotype as- 
sociated with memory/Ag-primed CD4 cells (1, 12, 13, 24). 
These data, representative of four experiments, suggest that 
MEL-14 treatment in vivo selectively  depleted naive CD4 cells 
from PLN. Splenic CD4 cells from MEL-14-treated mice 
also did not express L-selectin (Fig. 4 B), but in contrast to 
PLN, CD4 cells of otherwise naive phenotype (CD45RB  hi, 
CD44  l~  predominated. Although MEL-14  was present in 
serum (as indicated above), no background staining of CD4 
cells with anti-rat K secondary antibody was observed (not 
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Figure  2.  Failure to prime lymph node but not spleen CD4 
cells in MEL-14-av.ated mice. Periaortic lymph node and splenic 
CD4 cells were isolated from mice treated 6 d previously with 
either IgG2a or MEL-14,  I d before immunization with KLH 
as in Fig.  1.  Varying numbers of CD4 cells were cultured 
with 2  x  10  s KLH-pulsed APC. Proliferation (A) was mea- 
sured at 72 h. Supernatants were tested after 48 h  for Ib2 
(B) and IL-4 (C). 
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anti-CD3 after in vivo MEIA4 treat- 
ment. CD4 cells  isolated  from PLN (in- 
guinal, brachial, and periaortic) of  mice 
6 d after treatment with rat IgG2a or 
MEL-14 were tested for (/t) prolifera- 
tion and (B) cytokine production in re- 
sponse to platebound anti-CD3. In (A), 
CD4 cells  were cultured at the indicated 
numbers with  10  s  splenic APC  and 
were tested for proliferation at 72 h. In 
(B), 3.3  ￿  104 CD4 cells were cul- 
tured with 10  s APC, and supernatants 
were tested at 48 h for cytokines. 
shown).  The data suggest that L-selectin was lost from the 
surface of cells rather than masked.  Moreover,  since expres- 
sion of other  surface markers was unafected,  we conclude 
that the cells were not depleted by MEL-14 treatment,  but 
were  instead  diverted  to  the  spleen  and  other  sites. 
Discussion 
The results of this study demonstrate that when L-selectin 
is blocked by treatment with MEL-14 antibody in vivo, there 
is a profound depletion  of nucleated  cells from PLN and  a 
failure to generate primary immune responses in the lymph 
nodes draining  the site of Ag injection  (Fig.  1). Since CD4 
cells from PLN of MEL-H-treated mice are unable to generate 
primary  effector  cells,  as  measured  by  a  complete  lack  of 
priming  for proliferation  or cytokine  secretion  in response 
to  KLH  (Fig.  2),  the loss of responsiveness  is in  part  due 
to a blockade of naive CD4 cell migration  from the blood 
and potentially also to depletion of naive CD4 cells as well 
as other recirculating  lymphocytes from lymph nodes.  The 
data demonstrate that L-selectin is required for recirculation 
of naive CD4 cells to PLN,  confirming its function  in situ 
as the peripheral lymph node homing receptor.  When lym- 
phocyte trafficking via L-selectin is blocked during a primary 
response, neither naive CD4 cells nor responding, potentially 
circulating  CD4  cells,  are  able  to  use  alternative  adhesion 
receptors  to  migrate  into  PLN. 
Although  naive CD4 cells are not primed in PLN in the 
presence of ckculating MEL-14, the finding that normal KLH- 
spedfic primary effector CD4 cells are generated under  the 
same conditions in the spleen (Fig. 2) indicates that L-selectin 
does not play a role in trafficking to the spleen. Despite the lack 
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Figure 4.  MEL-14  treatment 
depletes naive  CD4 cells  from lymph 
node but not spleen. CD4 cells  from 
periaortic  lymph  node  (.4) and 
spleen (B) of mice treated 6 d previ- 
ously with IgG2a or MEL-14, and 
5 d pt~iously with KLH/CFA were 
stained with  the  indicated  anti- 
bodies, followed by FITC anti-rat 
K (RG7/9.1)  antibody, and  PE- 
anti-CD4.  Shown are histograms 
generated  by  gating  on  5,000 
CD4 + cells. Percent positive cells 
was  determined  on  the  basis of 
staining greater than that of isotype 
control antibodies, with the excep- 
tion of CD44 where high versus  low 
expression distinguishes CD4 sub- 
sets. The percent CD44 hi staining 
was determined with cursors set in 
(A) at 18 and 12 for lymph node 
CD4 cells from IgG2a-, and MEL- 
14-treated mice, respectively,  and in 
(B) at 16 for splenic  CD4 cells  from 
IgG2a- and MElct4-treated  mice. 
No binding of RG7/9.1  was ob- 
tained in the absence  of primary an- 
tibody (not shown), indicating that 
the rat antibodies that were present 
in vivo were not  adhering to the 
CD4 population at the time of iso- 
lation. 
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splenic CD4 cells exhibit typical levels of CD45RB and CD44 
expression, with a substantial proportion of the cells bearing 
a naive phenotype (Fig. 4). Together, the functional and pheno- 
typic data demonstrate that naive,  L-selectin-bearing CD4 
cells are not depleted by systemic exposure to MEL-14, but 
rather that L-selectin is shed from the surface or downregu- 
lated. When trafficking to PLN is blocked by MEL-14, naive 
CD4 cells can apparently localize and respond in other lym- 
phoid sites such as the spleen. This conclusion is strength- 
ened by the finding that the primary anti-KLH serum antibody 
response is delayed, but not blocked by MEL-14 treatment 
and that the development of KLH-specific memory CD4 cells 
is unaffected (not shown). 
In contrast to the spleen, PLN from MEL-14-treated mice 
are  depleted  of  CD4  cells  bearing  a  naive  phenotype 
(CD45RB hi, CD44 l~  and the residual CD4 population is 
comprised of small resting cells that express a memory pheno- 
type (CD45KB l~ CD44 hi) (Fig.  4).  Previously,  we showed 
that both resting and activated murine memory CD4 cells 
from the spleen lack L-selectin (12, 13). In addition, although 
circulating CD4 cells in both the blood and the thoracic duct 
lymph are predominantly L-selectin positive, KLH-specific 
memory is exclusively contained in the minor, L-selectin nega- 
tive subset (L. M. Bradley, unpublished observations). Since 
CD4 cells of memory phenotype remain in the PLN of MEL- 
14-treated animals, it appears that memory CD4 cells either 
do not use L-selectin for migration into PLN or only tran- 
siently express and use L-selectin to enter PLN during a sec- 
ondary response. It is also possible that the CD4 subset that 
remains in PLN after exposure to MEL-14 is nonrecirculating. 
It is probable that recirculation of naive CD4 cells is regu- 
lated by a multistep process that involves  combinations of 
adhesion molecules and their ligands. The paradigm for ex- 
travasation of cells across endothelium (reviewed in reference 
1) is based on neutrophil migration where cells are initially 
retarded in the blood flow by the transient binding of selectins 
to  their carbohydrate ligands.  The arrest of leukocytes is 
mediated by integrins subsequent to activation of the binding 
avidity by chemokines, such as IL-8, which bind to G-pro- 
tein-coupled receptors.  Integrin activation leads  to strong 
adhesion to endothelium and transmigration into tissue.  As 
both L-selectin and LFA-1  have been shown to play a role 
in the trafficking of lymphocytes to PLN (3, 26, and S. R. 
Watson, unpublished observations), and G-protein receptors 
are required for lymphocyte recirculation (27), the model de- 
veloped for neutrophil trafficking may also be valid for lym- 
phocyte recirculation. Thus, L-selectin expressed on naive CD4 
cells would mediate initial attachment to high endothelial 
venules of PLN. The results of our study indicate that it is 
possible to dramatically and selectively alter lymphocyte recir- 
culation by blocking a single adhesion pathway in vivo. The 
results underscore the therapeutic potential of selective mod- 
ification of lymphocyte trafficking by the use of antibodies 
to selectins  or their carbohydrate ligands. 
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